News coverage about PDL BioPharma (NASDAQ:PDLI) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. PDL BioPharma earned a news sentiment score of 0.13 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.296617320936 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of PDL BioPharma (NASDAQ PDLI) traded up $0.04 during trading hours on Friday, reaching $2.83. 958,900 shares of the company traded hands, compared to its average volume of 1,270,338. PDL BioPharma has a one year low of $1.96 and a one year high of $3.55. The stock has a market capitalization of $436.78, a price-to-earnings ratio of 5.66 and a beta of 0.46. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.16 and a quick ratio of 3.10.
PDL BioPharma (NASDAQ:PDLI) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.01. PDL BioPharma had a net margin of 24.51% and a return on equity of 9.20%. The company had revenue of $62.75 million during the quarter, compared to analyst estimates of $61.86 million. During the same period in the previous year, the business earned $0.08 earnings per share. The firm’s quarterly revenue was up 17.0% compared to the same quarter last year. equities analysts predict that PDL BioPharma will post 0.67 earnings per share for the current fiscal year.
PDLI has been the subject of a number of recent analyst reports. ValuEngine upgraded shares of PDL BioPharma from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. Cowen restated a “hold” rating and set a $3.00 price target on shares of PDL BioPharma in a research report on Friday, October 27th. BidaskClub lowered shares of PDL BioPharma from a “hold” rating to a “sell” rating in a research report on Saturday, January 6th. Finally, Zacks Investment Research lowered shares of PDL BioPharma from a “buy” rating to a “hold” rating in a research report on Monday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $3.33.
ILLEGAL ACTIVITY NOTICE: “PDL BioPharma (PDLI) Receives Media Impact Score of 0.13” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.com-unik.info/2018/01/12/pdl-biopharma-pdli-receives-media-impact-score-of-0-13.html.
About PDL BioPharma
PDL BioPharma, Inc seeks to provide return for its shareholders by acquiring and managing a portfolio of companies, products, royalty agreements and debt facilities in the biotechnology, pharmaceutical and medical device industries. The Company’s segments include income generating assets and product sales.
Receive News & Ratings for PDL BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PDL BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.